GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cingulate CING · USD

Health Care · US listing · 🇺🇸 United States

Compare

4.45

+4.46%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Cingulate

From its filings with the US Securities and Exchange Commission

SEC filings

Cingulate is based in Kansas City, Kansas and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CING. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $22.4m. At that date it held total assets of $15.1m and shareholders' equity of $2.5m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
7 Oct 2021
Employees
15
Head office
1901 W. 47TH PLACE, KANSAS CITY, KS, 66205
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. John RobertsChairman of the Board, since 2024$76,519
  • Dr. Shane SchafferChief Executive Officer, since 2012$770,327
  • Dr. Raul SilvaCo-Founder, Executive Vice President, Chief Science Officer
  • Dr. Matthew BramsCo-Founder, Executive Vice President, Chief Medical Officer, since 2012$267,727
  • Ms. Jennifer CallahanChief Financial Officer$446,065
  • Mr. Nilay PatelChief Legal Officer
  • Mr. Peter WerthDirector$47,775
  • Mr. Jeffrey ErvinIndependent Director$72,874
  • Mr. Jeff HargrovesIndependent Director$47,955
  • Mr. Bryan LawrenceIndependent Director$73,917
  • Mr. Thomas DaltonVice President, Investor and Public Relations, since 2023

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Cingulate Inc utilizes its precision timed release platform technology for drug delivery.
  • The firm develops two lead product candidates for the ADHD treatment market.
  • CTx-1301 and CTx-1302 combine three releases into one small tablet dosage form.

Weaknesses

  • The company currently employs only 15 full-time employees in the pharmaceutical sector.
  • Cingulate Inc is a small biopharmaceutical company with limited operational scale.
  • The firm focuses exclusively on the treatment of attention deficit hyperactivity disorder.

Opportunities

  • The company targets three core patient segments including children aged six to twelve.
  • Cingulate Inc aims to improve lives of patients suffering from commonly diagnosed conditions.
  • The firm can commercialize pharmaceutical products utilizing its unique drug release profiles.

Threats

  • The company went public on 7 October 2021 facing market volatility risks.
  • Cingulate Inc operates in the competitive Pharmaceuticals industry within the United States.
  • The firm relies on the successful development of its lead product candidates.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.